Randomized Phase III of PRRT Versus Interferon
NCT01860742
·
clinicaltrials.gov ↗
PHASE3
Phase
WITHDRAWN
Status
OTHER
Sponsor class
Conditions
Gastro-intestinal Neuroendocrine Tumors
Interventions
DRUG:
Interferon alpha-2b
DRUG:
177Lu-DOTATATE
Sponsor
Jules Bordet Institute